



ACTION REQUIRED

Adynovate® approved by Health Canada for patients less than 12 years of age
Customer Letter # 2019-01

2019-02-04

Dear Colleagues:

Please refer to the attached customer letter from Takeda/Shire with information related to the recent Health Canada approval for Adynovate® in children less than 12 years of age.

Several communications were issued over the past year, including customer letters and monthly PPP transition newsletters, that addressed the latest plasma protein product tender and subsequent product transitions. These announcements required patients with hemophilia A to transition from the extended half-life recombinant factor VIII product Eloctate® to another factor VIII product. Canadian Blood Services committed to the continued distribution of Eloctate® for patients who met specific access criteria (i.e., patients less than 12 years of age) until Adynovate® was approved for these patients.

With the Health Canada approval of Adynovate® for pediatric patients, patients less than 12 years of age currently receiving Eloctate® who have not been approved under any of the other exceptional access criteria are now required to transition to another factor VIII product. Canadian Blood Services provides a broad choice in factor VIII product selections with Adynovate®, Kovaltry®, Nuwiq® and Xyntha® available.

Canadian Blood Services will continue to partner with hemophilia treatment centres to ensure a timely and efficient transition of pediatric patients over the coming months. If required, exceptional patient access to Eloctate® will be considered on a case by case basis using the current named patient processes that were communicated via [customer letter 2018-34](#) on 2018-08-20.

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.

This customer letter can also be viewed at www.blood.ca in the “Hospitals Services” section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sincerely,

Mark Newburgh
Director, Integrated Supply Chain Planning